XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaboration, License, and Other Agreements - Summary (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues:        
Revenue $ 108,637 $ 103,747 $ 303,397 $ 296,623
Collaborative arrangements revenue        
Revenues:        
Revenue 108,637 103,747 303,397 295,798
Collaborative arrangement, other agreements        
Revenues:        
Revenue 365 547 1,254 1,359
Sale of active pharmaceutical ingredient        
Revenues:        
Revenue       825
AbbVie | Sale of active pharmaceutical ingredient        
Revenues:        
Revenue       228
AbbVie | North America | Collaborative arrangements revenue        
Revenues:        
Revenue 106,085 101,061 296,047 288,598
AbbVie | North America | Collaborative arrangement, collaboration and license agreements        
Revenues:        
Revenue 106,085 101,061 296,047 288,598
AbbVie | Europe and Other | Collaborative arrangement, collaboration and license agreements        
Revenues:        
Revenue 709 682 1,847 1,856
AstraZeneca | Collaborative arrangement, collaboration and license agreements        
Revenues:        
Revenue 144 219 484 629
AstraZeneca | Sale of active pharmaceutical ingredient        
Revenues:        
Revenue       597
Astellas Pharma Inc. | Collaborative arrangement, collaboration and license agreements        
Revenues:        
Revenue 520 555 1,543 1,621
Alnylam | Collaborative arrangement, co-promotion agreements        
Revenues:        
Revenue $ 814 $ 683 $ 2,222 $ 1,735